FORMULARY UPDATES ABUHB s Drug Formulary is at:
|
|
- Agnes Hudson
- 6 years ago
- Views:
Transcription
1 Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: Dear Gwent Prescriber At its last two meetings (5 th December 2013 and 23 rd January 2014) ABUHB s Medicines & Therapeutics Committee made the following decisions in relation to the ABUHB Formulary: FORMULARY UPDATES ABUHB s Drug Formulary is at: March 2014 BNF section 4.4 LISDEXAMFETAMINE mesylate ( Elvanse ) capsules ADDED for the treatment of ADHD (as part of a comprehensive treatment programme) in children 6 years when response to previous methylphenidate treatment is considered clinically inadequate. The MTC has designated lisdexamfetamine an Amber with Shared Care drug (i.e. specialist initiation only with Shared Care arrangements recommended for GP repeat prescribing) this is consistent with arrangements for prescribing methylphenidate and atomoxetine for ADHD and in accordance with AWMSG s recommendation. A Gwent Shared Care Protocol is in development. Full prescribing information on lisdexamfetamine at: BNF section LIXISENATIDE ( Lyxumia ) injection ADDED for the treatment of type 2 diabetes mellitus (in combination with oral glucose lowering medicines and/or basal insulin). The MTC has designated lixisenatide an Amber without Shared Care drug (appropriate only for initiation within a consultant led team or by accredited GPs with a special interest in diabetes including GPs based in practices that have a relevant accreditation to provide an advanced diabetic service). This recommendation is consistent with other GLP 1 agonists (exenatide and liraglutide) in the ABUHB Formulary. Comparative acquisition costs (from BNF March 2014) of GLP 1 agonists: Drug Dose Regimen Cost per year Lixisenatide 20microgram once daily 706 Liraglutide 1.2 once daily 955 Note NICE do not recommend 1.8mg once daily Exenatide m/r 2mg once weekly 954 Exenatide 5 to 10microgram twice daily 830 Doses are for general comparison and do not imply therapeutic equivalence. All GLP 1s are administered via subcutaneous injection. Full prescribing information on lixisenatide at: Page 1 of 5
2 BNF EXOREX lotion (coal tar solution 5% in an emollient basis) for psoriasis ADDED as a Formulary replacement for Alphosyl HC cream (a fixed combination of a tar with hydrocortisone and discontinued in September 2012). Although Exorex is not an exact equivalent to Alphosyl HC (as it contains no steroid) ABUHB Dermatology felt that a tar lotion was useful for patients with extensive psoriasis as it was easier to apply over a wider area than a cream. Exorex lotion is considered suitable for initiation by non specialist prescribers i.e. designated a Green drug. Full prescribing information on Exorex lotion is at: BNF TAPENTADOL modified release (Palexia SR ) The Traffic light recommendation has been changed from Red (Specialist only initiation and repeat prescribing) to Amber without Shared Care i.e. now considered appropriate for GP repeat prescribing but with the recommendation that only specialists in treating severe chronic pain should initiate it. Tapentadol film coated immediate release tablets and the oral solution remain non Formulary in Gwent as, in the absence of submissions to AWMSG for appraisal, they cannot be endorsed for use: Full prescribing information on tapentadol m/r tablets is at: OTHER PRESCRIBING NEWS SHARED CARE PROTOCOLS Prescribers should note the following changes to Gwent Protocols: ATOMOXETINE UPDATED to cover the initiation of treatment in adults with ADHD, in line with this license extension. METHYLPHENIDATE UPDATED to clarify the differential licensing of Concerta XL (now licensed for continuing ADHD treatment into adulthood) and to highlight that NICE CG72 recommends that (following a decision to start drug treatment in adults with ADHD) methylphenidate should normally be tried first (UNLICENSED use). Prescribers should also note that this Protocol does NOT cover the use of: methylphenidate in narcolepsy. methylphenidate at doses above the maximum recommended in ADHD. Medikinet XL in ADHD (non Formulary preparation). MELATONIN NEW Protocol covering the treatment of sleep onset insomnia and delayed sleep phase syndrome in children (UNLICENSED USE). DENOSUMAB 60mg (Prolia ) NEW Protocol (plus existing Local Enhanced Service funding) covering the prescribing, monitoring and administration of this monoclonal antibody in the treatment of osteoporosis in postmenopausal women. Prescribers should note that specialist requests to take on these responsibilities should only take place once the first dose of denosumab has been prescribed and administered within Secondary Care. All the Gwent Shared Care Protocols can be found at: OMEGA 3 FATTY ACID USE POST MI Prescribers should note that NICE CG172 (MI secondary prevention of November guidance.nice.org.uk/cg172) now states do not offer or advise people to use omega 3 fatty acid capsules (Omacor, Prestylon or Maxepa ) to prevent another MI. The previous position in NICE CG48 was to stop omega 3 fatty acids 4 years post MI. A letter communicating this change to practices is at: Page 2 of 5
3 PRESCRIBING ANALGESICS All local prescribing guidelines and resources (plus links to national pain resources) relating to pain management (palliative care excepted) are now available at: UPDATED NEUROPATHIC PAIN PATHWAY Following the publication of NICE CG173 Neuropathic pain pharmacological management in adults in non specialist settings in November 2013, the MTC reviewed the two local pathways for the treatment of neuropathic pain and diabetic peripheral neuropathic pain (DPNP). The two pathways have now been combined into a single one on one page. The pathway (one page) is at: TreatmentALGORITHM%5B31Jan2014%5D.pdf KEY POINTS TO NOTE ABOUT THE UPDATED NP/DPNP PATHWAY: The pathway now includes a recommendation NOT TO EXCEED 50mg OF AMITRIPTYLINE DAILY IF CO ADMINISTERED WITH AN SSRI The pathway supports use of the Brief Pain Inventory (Short Form) [at: files/news/briefpain_short.pdf] to assess pain with a note that improvement in function (question 9) may be more marked than improvement in the pain questions. The Pain Team in Secondary Care have agreed to provide GPs with the initial Brief Pain Inventory score so that improvements can be determined. The pathway no longer includes the advice that Versatis can play a role as a rescue analgesic (while waiting for a referral to a specialist pain service) in a very small subgroup of people with localised pain unable to take oral medication, as this is no longer a recommendation in CG173. CHRONIC PERSISTENT PAIN and TRAMADOL New advice in the form of 10 KEY MESSAGES covering each of the following topics is now available: the use of strong opiates in chronic persistent pain, the general management of chronic persistent pain tramadol These messages are all in one 3 page document at: TramadolStrongOpiates%26CPPfinalFeb2014.pdf TRAMADOL Tramadol educational resource materials produced by the All Wales Therapeutic and Toxicology Centre (AWTTC) and All Wales Prescribing Advisory Group (AWPAG) are now available. The purpose of these resources is to raise awareness amongst prescribers and patients of the potential harms associated with the misuse and diversion of tramadol, and to provide healthcare professionals with information and training to aid in the appropriate prescribing of tramadol as part of an overall pain management strategy. The resources can be found at: They include: Initial prescribing analysis Audit Materials Educational Slide Set WeMeReC Maps and WeMeReC Things to Know Patient Information Leaflet Shared Decision Making Toolkit If you require a Word or PowerPoint version of any of the materials please contact awttc@wales.nhs.uk Page 3 of 5
4 COPD A Stepped approach to management in Primary Care The MTC has endorsed a new one page guide setting out the stepped management of COPD in Primary Care. It includes referral criteria and inhaler options. The plan is to update this as new inhalers become available through 2014 and beyond. A copy of the guide (1 page) is at: PrimaryCare10Jan2014.pdf CAPTOPRIL 5mg/5ml and 25mg/5ml sugar free oral solutions (Noyada ) There is now a licensed captopril liquid for children covering the same indications as captopril tablets: pharma launches noyada first licensed oral liquid solution captopril/ Those practices with patients on the oral suspension should consider changing them over to the licensed oral solution formulation. NHS costs for the solution are for 100ml of 25mg/5ml and for 100ml of 5mg/5ml Full prescribing information on Noyada is at: SWITCHING Antiepileptic Drugs advice on LEVETIRACETAM (Keppra ) Further to the news item in the MTC s autumn enewsletter (November 2013) highlighting the MHRA s guidance on prescribing antiepileptic drugs (AEDs), local specialist advice on levetiracetam has been issued. The key prescribing point from this is: Levetiracetam is in category 3, which means that it is usually unnecessary to ensure that patients are maintained on a specific manufacturer s product, unless there are specific concerns such as patient anxiety, and risk of confusion or dosing errors. The full advice on levetiracetam is available at: GenericPrescribingLetterMarch2014.pdf NICE BNF and BNFC Apps for Apple and Android devices To get these Apps you need an NHS Wales Athens account. To set one of these accounts up go to: The BNF Apps provide downloadable content and can operate even if there is no network access. The Apps (like the online version of the BNF are updated each month in contrast to the now annually distributed print versions of the BNF and BNFC. BNF: Android smartphone and tablet users BNF: iphone and ipad users BNFC: Android smartphone and tablet users BNFC: iphone and ipad users NICE are currently conducting a public consultation on its vision for an enhanced BNF service, and if you want to submit your views there is still time as the consultation will run to 9am on 31 March See for more information: Page 4 of 5
5 DRONEDARONE (Multaq ) All Wales advice that dronedarone should be prescribed and monitored by specialist teams only (a Red drug) was reviewed by AWMSG and it was agreed that this prescribing status recommendation should remain unchanged. Dronedarone is only licensed for the maintenance of sinus rhythm after successful cardioversion in adult clinically stable patients with paroxysmal or persistent AF (after other treatment options have been considered). See: REVIEW of High Intensity STATINS for Acute Coronary Syndrome (ACS) REMINDER OF 2012 GUIDANCE The MTC s Summer enewsletter of 2012 (circulated in August 2012) contained the following advice for patients with ACS: Patients with ACS should be assessed according to their co morbidities and if deemed appropriate by the cardiology team then they should be offered atorvastatin 80mg daily as a high intensity statin treatment for THREE MONTHS duration post ACS. THREE MONTHS after ACS, the statin dose should be reviewed. If initial cholesterol was <7.5mmol/L then switch to simvastatin 40mg daily or a drug of similar acquisition cost. If there are potential drug interactions or simvastatin 40mg is contraindicated, offer a lower dose of simvastatin or pravastatin. If initial cholesterol was 7.5mmol/L then switch to atorvastatin 40mg daily and consider referral to the lipid clinic for screening if any suggestion of familial hyperlipidaemia. Patients with a recorded total cholesterol (TC) >5mmol/L at three months post ACS event (despite treatment with atorvastatin 80mg daily) should be EXCLUDED FROM SWITCH ING, continued on high intensity atorvastatin and referred to the lipid clinic for assessment and possible family screening. The full ABUHB guidance (1 page) is available at: ABHBprotocol%5BFeb12%5D.pdf Feedback on any item in this enewsletter is welcome. Suggested agenda items for the MTC are also welcome. Follow Trevor Batt Pharmacist & Professional Secretary to: Aneurin Bevan HB Medicines & Therapeutics Committee Aneurin Bevan Health Board Based at Victoria House, Corporation Rd, Newport NP19 0BH trevor.batt@wales.nhs.uk Tel: (DIRECT LINE) Page 5 of 5
Aneurin Bevan Health Board Medicines & Therapeutics Committee. enewsletter
Aneurin Bevan Health Board Medicines & Therapeutics Committee August 2013 enewsletter Dear Gwent Prescriber At its last two meetings (23 rd May and 11 th July) ABHB s Medicines & Therapeutics Committee
More informationGWENT FORMULARY DECISIONS
Dear Gwent Prescriber At its last two meetings (9 th September and 21 st October 2010) the Gwent Partnership Medicines & Therapeutics Committee (GPMTC) made the following decisions in relation to the Aneurin
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee July 2014 PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Methylphenidate in the treatment of Attention Deficit Hyperactivity Disorder in Children, Young People and Adults Implementation Date: June 2015 Review Date: June 2017 This guidance
More informationNorth of Tyne Area Prescribing Committee DECISION SUMMARY North of Tyne Area Prescribing Committee Summary of decisions made regarding new product requests considered at a meeting of the Committee on Tuesday
More informationVolume 2; Number 11 July 2008
Volume 2; Number 11 July 2008 CONTENTS Page 1 NICE Clinical Guideline 67: Lipid Modification (May 2008) Page 7 NICE Technology Appraisal 132: Ezetimibe for the treatment of primary (heterozygous familial
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
ANEURIN BEVAN UNIVERSITY HEALTH BOARD MEDICINES & THERAPEUTICS COMMITTEE PRESCRIBING enewsletter 28 September 2016 ARCHIVE at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 Dear Gwent Prescriber
More informationMethylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement
Methylphenidate Shared Care Agreement For attention deficit hyperactivity disorder (ADHD) in adults Effective Shared Care Agreement Section 1: Shared Care arrangements and responsibilities Section 1.1
More informationLondon Medicines Information Service
London Medicines Information Service Extended-release methylphenidate a review of the pharmacokinetic profiles available March 2018 First authored by Martin Bradley (martin.bradley@gstt.nhs.uk) May 2016
More informationGWENT FORMULARY DECISIONS
Dear Gwent Prescriber At its last two meetings (13 th October and 24 th November 2011) ABHB s Medicines & Therapeutics Committee (formerly GPMTC) made the following decisions in relation to the ABHB Joint
More informationAdult Neurodevelopmental Services. ADHD Shared Protocol
Adult Neurodevelopmental Services ADHD Shared Protocol Issue 1: April 2016 1 2 Adult Neurodevelopmental Service Shared Care Protocol for Adult Attention Deficit Hyperactivity Disorder (ADHD) 1. BACKGROUND
More informationGWENT FORMULARY DECISIONS
Dear Gwent Prescriber At its last three meetings (12 th January, 1 st March and 19 th April 2012) ABHB s Medicines & Therapeutics Committee (formerly GPMTC) made the following decisions in relation to
More informationDRAFT. Consultees are asked to consider and comment on the CEPP National Audit: Antipsychotics in Dementia document.
Enclosure No: Agenda item No: Author: Contact: xx/xxxxx/xxxx0918 xx CEPP National Audit: Antipsychotics in Dementia All Wales Therapeutics and Toxicology Centre Tel: 02920 71 6900 awttc@wales.nhs.uk 1.0
More informationIssue date September 2010 (Reviewed October 2013) Clinicians from Andrew Lang Centre, Mental. Specialist Pharmacist & Formulary Pharmacist
Title Document Type Issue no Shared care guidelines in the Treatment of Attention Deficit/ Hyperactivity Disorders Shared Care Guidelines and Information for GPs Clinical Governance Support Team Use Issue
More informationPregabalin Prescribing in Primary Care Audit Results 2012/13
Executive summary Pregabalin Prescribing in Primary Care Audit Results 2012/13 Pregabalin is extensively used across Aneurin Bevan Health Board (ABHB). It is the second highest medicine in terms of primary
More informationPersistent Pain Resources. Educational Slide Set
Persistent Pain Resources Educational Slide Set October 216 This document has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory Group (AWPAG)
More informationGuidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults
Guidance on Safe Prescribing of Melatonin for Sleep Disorders in Children, Young People and Adults Ref: PHARM-0025-v3 Status: FINAL Document type: Guidelines Guidance on Safe Prescribing of Melatonin Page
More informationNeuropathic Pain Treatment Guidelines
Neuropathic Pain Treatment Guidelines Background Pain is an unpleasant sensory and emotional experience that can have a significant impact on a person s quality of life, general health, psychological health,
More informationNHS WALES PRIMARY CARE PRESCRIBING ANALYSIS FOR TRAMADOL DATA TO SEPTEMBER 2014
NHS WALES PRIMARY CARE PRESCRIBING ANALYSIS FOR TRAMADOL DATA TO SEPTEMBER 2014 March 2015 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales
More informationSHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD)
SHARED CARE PROTOCOL FOR THE PRESCRIBING AND MONITORING OF MEDICINES FOR ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) 1. Introduction This protocol describes how patients prescribed medicines for ADHD
More informationAppendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children
Appendix 4I - Melatonin Guidance for the treatment of sleep-wake cycle disorders in children Background Sleep disturbance in children with neurological or behavioural disorders is common and can be a major
More informationPRESCRIPTION PAD. The Newsletter of the Cumbria Area Prescribing Committee. February 2012 No. 18. Click here to find more. News from the MHRA
PRESCRIPTION PAD The Newsletter of the Cumbria Area Prescribing Committee February 2012 No. 18 Click here to find more Clinical policy and Formulary news Lothian changes Targeted Medication Use Reviews
More informationESCA: Denosumab for the treatment of osteoporosis in postmenopausal women.
ESCA: Denosumab for the treatment of osteoporosis in postmenopausal women. Specialist details Patient identifier Name Tel: This effective shared care agreement (ESCA) sets out details for the sharing of
More informationLipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention)
Lipid Lowering in patients with High Risk of Cardiovascular Disease (Primary Prevention) Policy Statement: October 2010 This policy defines the decision made by NHS Wirral following an evidence review
More informationEFFECTIVE SHARE CARE AGREEMENT. FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY
Specialist details Patient identifier Name Tel: EFFECTIVE SHARE CARE AGREEMENT FOR THE off license use of GLP1 mimetics in combination with insulin IN DUDLEY The aim of Effective Shared Care Guidelines
More informationSHARED CARE PRESCRIBING GUIDELINE
Approval date: September 2018. Document review date: September 2021 or sooner if evidence/practice changes g SHARED CARE PRESCRIBING GUIDELINE Methylphenidate, atomoxetine, lisdexamfetamine, dexamfetamine
More informationReview guidance for patients on long-term amiodarone treatment
Review guidance for patients on long-term amiodarone treatment This review guidance document has been produced in response to: 1. Current supply shortages of branded and generic versions of 100mg and 200mg
More informationCEPP National Audit Antipsychotics in Dementia
CEPP National Audit Antipsychotics in Dementia December 2018 This document has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory Group (AWPAG)
More informationThe All Wales Medicine Strategy Group (AWMSG) is asked to support implementation of the following prescribing indicators.
ENCLOSURE 5 APPENDIX 1 Paper presented to AWMSG in June 2006 AWPAG considered comments recorded in AWMSG minutes in July 2006 Paper subsequently updated and brought back to AWMSG for endorsement This paper
More informationMELATONIN Information for Primary Care
North of Tyne Area Prescribing Committee Shared Care Group MELATONIN Information for Primary Care Background Melatonin is a hormone secreted by the pineal gland. It is normally secreted at night and its
More informationrosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd.
rosuvastatin, 5mg, 10mg, 20mg, film-coated tablets (Crestor ) SMC No. (725/11) AstraZeneca UK Ltd. 09 September 2011 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product
More informationFormulary and Prescribing Guidelines
Formulary and Prescribing Guidelines SECTION 3: TREATMENT OF BIPOLAR AFFECTIVE DISORDER This section provides information regarding the pharmacological management of Bipolar affective disorder in secondary
More informationGENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY
GENERIC MEDICINES (Non-Innovator Brand) PRESCRIBING POLICY First issued by/date Issue Version Purpose of Issue/Description of Change Planned Review Date August 2018 1.0 Promoting generic prescribing whenever
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Shared Care Guideline for the prescribing and monitoring of Antipsychotics for the treatment of Schizophrenia and psychotic symptoms in children and adolescents Scope: Pennine
More informationPersistent Pain Resources. Ten Key Messages
Persistent Pain Resources Ten Key Messages October 2016 This document has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory Group (AWPAG) and
More informationthe person is intolerant of either metformin or a sulphonylurea, or treatment with metformin or a sulphonylurea is contraindicated, and
Exenatide (Byetta) and Liraglutide (Victoza) prescribing guidance: Notes for initiation in primary care These incretin mimetics are given by subcutaneous injection once or twice daily. They have similar
More informationConduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA)
E102 Conduct Disorder in Children and Young People (CYP 5-18 years of age) RISPERIDONE Effective Shared Care Agreement (ESCA) Patient details Name: Date of birth: NHS number: Contact details Specialist:
More informationPatient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015
Patient and Public Reference Group for Medicines ADTC Sub-group NHS Tayside 17 th February 2015 Claire James, Senior Pharmacist Clinical Effectiveness, Ninewells Hospital Aims To increase awareness and
More informationChild and Adolescent Mental Health Services (CAMHS)
Child and Adolescent Mental Health Services (CAMHS) Effective shared care agreement (ESCA) for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) with METHYLPHENIDATE This form must be completed
More informationPrescribing of Denosumab (Prolia ) in Wales: Review. Full document
Prescribing of Denosumab (Prolia ) in Wales: Review Full document October 2013 This report has been prepared by a multiprofessional collaborative group, with support from the All Wales Prescribing Advisory
More informationNational Prescribing Indicators Annual Primary Care Prescribing Report
National Prescribing Indicators 214 215 Annual Primary Care Prescribing Report This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales Therapeutics
More informationMETHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE
NOTTINGHAMSHIRE AREA PRESCRIBING COMMITTEE SHARED CARE PROTOCOL AGREEMENT METHYLPHENIDATE AND ATOMOXETINE TREATMENT OF ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN AND YOUNG PEOPLE OBJECTIVES To
More informationNATIONAL PRESCRIBING INDICATORS ANALYSIS OF PRESCRIBING DATA TO DECEMBER 2014
NATIONAL PRESCRIBING INDICATORS 2014 2015 ANALYSIS OF PRESCRIBING DATA TO DECEMBER 2014 May 2015 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All
More information7 th November % of patients had lidocaine plasters prescribed for the licensed indication of post herpatic neuralgia
Directorate of Integrated Care Health and Social Care Board 12-22 Linenhall Street Belfast BT2 8BS Tel : 028 90553782 Fax : 028 90553622 Web Site: www.hscboard.hscni.net 7 th November 2013 Dear colleague
More informationCoronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol)
CLINICAL GUIDELINE Coronary Heart Disease and Stroke, Primary and Secondary Prevention Guidelines (Cholesterol) A guideline is intended to assist healthcare professionals in the choice of disease-specific
More informationA new model for prescribing varenicline
Pharmacist Independent Prescribers in partnership with A new model for prescribing varenicline Dear Stop Smoking Advisor You will be aware of the stop smoking drug varenicline that goes under the brand
More informationGREATER MANCHESTER INTERFACE PRESCRIBING GROUP
GREATER MANCHESTER INTERFACE PRESCRIBING GROUP On behalf of the GREATER MANCHESTER MEDICINES MANAGEMENT GROUP SHARED CARE GUIDELINE FOR THE PRESCRIBING OF SELECTIVE SEROTONIN REUPTAKE INHIBITORS (SSRIs)
More informationSHARED CARE GUIDELINE
SHARED CARE GUIDELINE Title: Lithium Treatment in Adults aged 18-65 years Scope: Pennine Care NHS Foundation Trust NHS Bury NHS Oldham NHS Heywood, Middleton and Rochdale NHS Stockport NHS Tameside & Glossop
More informationJob Title Name Signature Date. Director of Nursing Angela Wallace Signed Angela Wallace 30/6/2014
PATIENT GROUP DIRECTIONS FOR SUPPLY OF VARENICLINE (CHAMPIX ) BY AUTHORISED COMMUNITY PHARMACISTS WORKING IN FORTH VALLEY Protocol Number 445 Version 1 Date protocol prepared: June 2014 Date protocol due
More informationAtomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD)
Atomoxetine Effective Shared Care Agreement For Attention Deficit Hyperactivity Disorder (ADHD) Section 1: Shared Care arrangements and responsibilities Section 1.1 Agreement to transfer of prescribing
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR ALCOHOL DEPENDENCE INDICATION Naltrexone is used as part of a comprehensive programme of treatment against alcoholism to reduce the
More informationEXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens
EXENATIDE (BYETTA ) PROTOCOL, 5mcg and 10mcg SC injection pre-filled pens This document should be read in conjunction with the current Summary of Product Characteristics http://www.medicines.org.uk 1.
More informationPrescribing Framework for Naltrexone in Alcohol Relapse Prevention
Prescribing Framework for Naltrexone in Alcohol Relapse Prevention Patients Name:.. NHS Number: Patients Address:... (Use addressograph sticker) GP s Name:... Communication We agree to treat this patient
More informationA Suite of Enhanced Services for. Prudent Structured Care for Adults with Type 2 Diabetes
An Enhanced Service for Prudent Structured Care for Adults with Type 2 Diabetes Page 1 A Suite of Enhanced Services for Prudent Structured Care for Adults with Type 2 Diabetes 1. Introduction All practices
More informationNICE update. Paul Chrisp, Programme Director, Medicines and Prescribing Centre
NICE update Paul Chrisp, Programme Director, Medicines and Prescribing Centre Outline NICE offers a comprehensive suite of guidance, advice and support for delivering quality, safety and efficiency in
More informationMedicines Management Team Prescription Clerk Training Event
Medicines Management Team Prescription Clerk Training Event Sanjeev Sharma and Marie M c Ilwain September 2017 Introductions Medicines Waste Question-what happens to unused medicines that are returned
More informationShared Care Guideline. The Management of Epilepsies in Children
THE SOUTH YORKSHIRE & BASSETLAW Shared Care Guideline For The Management of Epilepsies in Children Shared care guideline developed by: Sheffield Children's NHS Foundation Trust; Dr P Baxter Consultant
More informationOpioid rotation or switching may be considered if a patient obtains pain relief with one opioid and is suffering severe adverse effects.
Dose equivalence and switching between opioids Key Messages Switching from one opioid to another should only be recommended or supervised by a healthcare practitioner with adequate competence and sufficient
More informationEvidence. Advice, guidance and standards. Evidence
8 Annual Report 2011 Advice, guidance and standards We develop evidence-based advice, guidance and standards to support improvements in the quality of healthcare people receive. Working with national and
More informationBRISTOL-MYERS SQUIBB and ASTRAZENECA v SANOFI
CASE AUTH/2638/9/13 and AUTH/2639/9/13 BRISTOL-MYERS SQUIBB and ASTRAZENECA v SANOFI Promotion of Lyxumia Bristol-Myers Squibb and AstraZeneca jointly complained about cost comparison claims in a Lyxumia
More informationFORMULARY UPDATES ABUHB s Drug Formulary is at:
Aneurin Bevan University Health Board Medicines & Therapeutics Committee PRESCRIBING enewsletter archive at: http://www.wales.nhs.uk/sites3/page.cfm?orgid=814&pid=48407 September 2015 Dear Gwent Prescriber
More informationPATIENT GROUP DIRECTION
PATIENT GROUP DIRECTION FOR THE SUPPLY OF VARENICLINE (CHAMPIX ) TO ADULTS OVER 18 YEARS OF AGE BY COMMUNITY PHARMACISTS UNDER THE PUBLIC HEALTH SERVICE - SMOKING CESSSATION SERVICE IN NHS HIGHLAND THE
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Peripheral arterial disease Potential output:
More informationALL WALES PRESCRIBING ADVISORY GROUP
Enclosure No: 5/AWMSG/1114 Agenda Item No: 9 Minutes of AWPAG Meeting 24 th September 2014 Author: Chairman, AWPAG Contact: Tel: 029 20716900 E-Mail: awttc@wales.nhs.uk ALL WALES PRESCRIBING ADVISORY GROUP
More informationDENOSUMAB SHARED CARE GUIDLINES
DENOSUMAB LICENSING Denosumab (PROLIA ) is licensed for the treatment of osteoporosis in postmenopausal women at increased risk of fractures and for bone loss associated with hormone ablation in men with
More informationLincolnshire Prescribing and Clinical Effectiveness Bulletin
S Lincolnshire Prescribing and Clinical Effectiveness Bulletin Volume 12 No 10, November 2018 Optum in association with Lincolnshire Clinical Commissioning Groups, Lincolnshire Community Health Services,
More informationKiran Hewitt Katie Sims. Dr Alex Day. Reviewed By Ozma Tahir Lead Medicines Information and Clinical Economy Pharmacist, BHFT
Prescribing Arrangements for the use of methylphenidate, atomoxetine, lisdexamfetamine and amfetamine in adult ADHD (attention deficit hyperactivity disorder) in Berkshire For all referrals of adults with
More informationVolume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008)
Volume 2; Number 14 September 2008 NICE CLINICAL GUIDELINE 66: TYPE 2 DIABETES THE MANAGEMENT OF TYPE 2 DIABETES (MAY 2008) The purpose of this special edition of the PACE Bulletin is to summarize the
More informationSHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE
SHARED CARE GUIDELINE FOR THE MANAGEMENT OF PATIENTS ON NALTREXONE FOR OPIOID DEPENDENCE INDICATION Naltrexone is a pure opiate antagonist licensed as an adjunctive prophylactic therapy in the maintenance
More informationEssential Shared Care Agreement Naltrexone
In partnership with as part of Please complete the following details: Patient s name, address, date of birth Consultant s contact details (p.3) And send One copy to: 1. The patient s GP 2. Put one copy
More informationThey are updated regularly as new NICE guidance is published. To view the latest version of this NICE Pathway see:
Ongoing care for adults with psychosis or schizophrenia bring together everything NICE says on a topic in an interactive flowchart. are interactive and designed to be used online. They are updated regularly
More informationBuccal Midazolam For the treatment of prolonged epileptic seizures, clusters of epileptic seizures and status epilepticus.
Oxfordshire Clinical Commissioning Group, Oxford University Hospitals NHS Trust and Oxfordshire Health NHS Foundation Trust Shared Care Protocol and Information for GPs Buccal Midazolam For the treatment
More informationMONITORING OF MEDICINES APPRAISED BY NICE AND AWMSG SUMMARY
MONITORING OF MEDICINES APPRAISED BY NICE AND AWMSG SUMMARY April 2014 This report has been prepared by the Welsh Analytical Prescribing Support Unit (WAPSU), part of the All Wales Therapeutics and Toxicology
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE QUALITY AND OUTCOMES FRAMEWORK (QOF) INDICATOR DEVELOPMENT PROGRAMME Briefing paper QOF indicator area: Primary prevention of CVD Potential output:
More informationBerkshire West Area Prescribing Committee Guidance
Guideline Name Berkshire West Area Prescribing Committee Guidance Date of Issue: September 2015 Review Date: September 2017 Date taken to APC: 2 nd September 2015 Date Ratified by GP MOC: Guidelines for
More informationMELATONIN Insomnia and Sleep Disorders in Children
DOCUMENT TO BE SCANNED INTO ELECTRONIC RECORDS AS AND FILED IN NOTES Patient Name : Date of Birth: NHS No: Name of Referring Consultant: Contact number: INTRODUCTION Melatonin is a pineal hormone which
More informationNHS Kent and Medway Medicines Management. Dronedarone (Multaq ) Shared Care Guideline For Prescribing
NHS Kent and Medway Medicines Management Dronedarone (Multaq ) Shared Care Guideline For Prescribing Issue No: 2 Review Date (If Applicable): Accountable Officer: Heather Lucas Contact Details: 01233 618158
More informationNottinghamshire Joint Formulary Group Meeting Minutes 9 th October 2014, 2-5pm Room 1, Hawthorne House NG18 4LE
Nottinghamshire Joint Formulary Group Meeting Minutes 9 th October 2014, 2-5pm Room 1, Hawthorne House NG18 4LE Present: Steve May (SM) Chief Pharmacist, SFHT (chair); Amanda Rawlings (AR) Prescribing
More informationMid Essex Locality Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care
Guideline for Management of Adult Acute and Chronic Non-Cancer Pain in Primary care If possible patients should be assessed using a simple visual analogue scale VAS to determine the most appropriate stage
More informationDenosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis. Date: Date:
Denosumab (Prolia 60 mg) Effective Shared Care Agreement For the treatment of Osteoporosis Section 1: Shared care arrangements and responsibilities Section 1.1 Agreement for transfer of prescribing to
More informationNeuropathic pain MID ESSEX LOCALITY
Neuropathic pain Neuropathic pain is defined as pain caused by a lesion or disease of the somatosensory nervous system. A. Leeds Assessment of Neuropathic Symptoms and Signs (LANSS) i Read questions to
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINES FOR PRESCRIBING OF METHYLPHENIDATE IN ATTENTION DEFICIT HYPERACTIVITY DISORDER IN CHILDREN INDICATION Methylphenidate is generally regarded as a first line choice of treatment for
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE SCOPE
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE 1 Guideline title SCOPE Neuropathic pain pharmacological management: the pharmacological management of neuropathic pain in adults in non-specialist
More informationSHARED CARE AGREEMENT: MELATONIN (CHILDREN)
NB: This document should be read in conjunction with the current Summary of Product Characteristics (SPC) where appropriate. DRUG AND INDICATION: Generic drug name: Formulations: MELATONIN 3mg immediate
More informationNHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification
NHS FORTH VALLEY LOCAL ENHANCED SERVICE (2010) Rationale General Practitioner Prescribing Service (GPPS) Opiate Assisted Treatment Service Specification Aims It is the responsibility of general practitioners
More informationScottish Medicines Consortium
Scottish Medicines Consortium saxagliptin, 5mg film-coated tablet (Onglyza ) No. (603/10) Bristol-Myers Squibb Pharmaceuticals Ltd 05 February 2010 The Scottish Medicines Consortium (SMC) has completed
More informationInformation leaflet for primary care: Agomelatine
Information leaflet for primary care: Agomelatine Background information Agomelatine is an antidepressant indicated for the treatment of major depressive episodes in adults. Agomelatine is a melatonin
More informationPrimary care review of Tramadol Prescribing
Primary care review of Tramadol Prescribing Aim of the Audit To ensure the prescribing of tramadol is safe, appropriate and regularly reviewed, in line with local chronic pain guidelines 1 Background Tramadol
More informationPrimary Prevention Patients aged 85yrs and over
Rotherham Guideline for the management of Non-Familial Hypercholesterolaemia Type 1 Diabetes Offer lifestyle advice Over 40yrs of age? Diabetic for more than 10 years? Established nephropathy? Other CVD
More informationAPPENDIX 2F Management of Cholesterol
Patients with established CVD: Coronary heart disease Cerebrovascular disease Peripheral vascular disease APPEDIX 2F Management of Cholesterol Patients at high risk of cardiovascular events: Chronic kidney
More informationPaediatric Prescribing Pocket Guide September 2014 (Version 1)
PAGE 1 Paediatric Prescribing Pocket Guide September 2014 (Version 1) In children, the risk of medication errors is often exacerbated by the need for calculations to determine the dose. Prescribing errors
More informationGG&C Chronic Non Malignant Pain Opioid Prescribing Guideline
GG&C Chronic Non Malignant Pain Opioid Prescribing Guideline Background Persistent pain is common, affecting around five million people in the UK. For many sufferers, pain can be frustrating and disabling,
More informationCardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57
Cardiff & Vale (C&V) UHB Corporate Medicines Management Group (c MMG) SHARED CARE DRUG: LISDEXAMFETAMINE PROTOCOL NUMBER: CV 57 INDICATION: Attention deficit hyperactivity disorder (ADHD) as part of a
More informationIxekizumab for treating moderate to severe plaque psoriasis [ID904]
Thank you for agreeing to make a submission on your organisation s view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective on the technology
More informationMODULE 1: BASIC DRUG KNOWLEDGE
MODULE 1: BASIC DRUG KNOWLEDGE 1.1 How Drugs Work A drug is a medicine or substance (but not food or water) which when ingested (or otherwise introduced into the body) alters the way the body works physically
More informationBournemouth, Dorset and Poole Prescribing Forum
SHARED CARE GUIDELINE FOR THE USE OF ATOMOXETINE IN ADULTS WITH ATTENTION DEFICIT HYPERACTIVITY DISORDER INDICATION Atomoxetine is a non-stimulant non-amphetamine inhibitor of noradrenaline reuptake. It
More information